Free Trial

Xeris Biopharma (XERS) News Today

Xeris Biopharma logo
$4.94 +0.17 (+3.45%)
As of 11:08 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XERS Latest News

Xeris Biopharma Holdings, Inc. stock logo
Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Millennium Management LLC increased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 34.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,948,552 shares of the company's stock after acqu
Xeris Biopharma Holdings, Inc. stock logo
BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
BNP Paribas Financial Markets bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 100,012 shares of the company's stock, valued at approximately $339,000. BNP
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen lowered Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday.
Xeris Biopharma Holdings, Inc. stock logo
Stonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Stonepine Capital Management LLC bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 182,317 shares of the company's stock, valued at ap
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.
D. E. Shaw & Co. Inc. grew its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 38.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,363,452 shares of the company's stock after buying an ad
Xeris Biopharma Holdings, Inc. stock logo
Leerink Partnrs Weighs in on Xeris Biopharma Q2 Earnings
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Xeris Biopharma in a note issued to investors on Monday, May 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will earn ($0.01)
Xeris Biopharma Holdings, Inc. stock logo
Parkman Healthcare Partners LLC Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Parkman Healthcare Partners LLC raised its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 465.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 578,511 shares of the company's stock
Xeris Biopharma Holdings, Inc. stock logo
Schonfeld Strategic Advisors LLC Lowers Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Schonfeld Strategic Advisors LLC reduced its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 40.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,000 shares of th
Xeris Biopharma Holdings, Inc. stock logo
Driehaus Capital Management LLC Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Driehaus Capital Management LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 594,015 shares of the company's stock, valued
Xeris Biopharma Holdings, Inc. stock logo
Tudor Investment Corp ET AL Reduces Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Tudor Investment Corp ET AL cut its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 39.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 305,186 shares of the company's stock after selling 202,171 shares during th
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Reduced by Caxton Corp
Caxton Corp cut its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 60.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,015,157 shares of the company's stock aft
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (XERS) Projected to Post Earnings on Thursday
Xeris Biopharma (NASDAQ:XERS) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-xeris-pharmaceuticals-inc-stock/)
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase - Time to Buy?
Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - What's Next?
Xeris Biopharma Holdings, Inc. stock logo
JPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
JPMorgan Chase & Co. increased its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 166.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,043,441 shares of t
Xeris Biopharma Holdings, Inc. stock logo
Renaissance Technologies LLC Raises Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Renaissance Technologies LLC grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 31.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,098,840 shares of the company's stock after buying an additional 500,120 shares during
Xeris Biopharma Holdings, Inc. stock logo
EAM Investors LLC Buys New Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
EAM Investors LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 222,377 shares of the company's stock, val
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Trading Down 4.9% - Here's What Happened
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 4.9% - Time to Sell?
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short Interest
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 17,040,000 shares, an increase of 52.0% from the March 15th total of 11,210,000 shares. Based on an average daily trading volume, of 2,810,000 shares, the days-to-cover ratio is currently 6.1 days. Currently, 12.0% of the shares of the stock are sold short.
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Shares Up 4.9% - What's Next?
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% - Here's What Happened
Xeris Biopharma Holdings, Inc. stock logo
Kennedy Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Kennedy Capital Management LLC boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 10.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 666,095 shares of the
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc.
Vanguard Group Inc. increased its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,899,063 shares of the company's stock after purchasing an additional 1
Xeris Biopharma Holdings, Inc. stock logo
CenterBook Partners LP Sells 2,791,929 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
CenterBook Partners LP reduced its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 80.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 690,077 shares of the company's stock after selling 2,791,929 shares during the period. CenterBook
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's Why
Xeris Biopharma (NASDAQ:XERS) Shares Down 6.2% - Should You Sell?
Xeris Biopharma Holdings, Inc. stock logo
AIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
AIGH Capital Management LLC raised its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 17.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,574,846 shares of the company's stock aft
Xeris Announces Changes to Its Board of Directors
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - Still a Buy?
Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - Time to Buy?
Xeris Biopharma Holdings, Inc. stock logo
Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 106.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,332 shares of
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 Shares
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's Why
Xeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's What Happened
12 Best Stocks to Invest in for a Stock Market Game
Xeris Biopharma Holdings, Inc. stock logo
Xeris Biopharma (NASDAQ:XERS) Sets New 12-Month High - Still a Buy?
Xeris Biopharma (NASDAQ:XERS) Hits New 52-Week High - Here's What Happened
Xeris Biopharma Holdings, Inc. stock logo
Globeflex Capital L P Takes $424,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Globeflex Capital L P purchased a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 125,210 shares of the company's stock
Get Xeris Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.

XERS Media Mentions By Week

XERS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

XERS
News Sentiment

0.95

0.87

Average
Medical
News Sentiment

XERS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

XERS Articles
This Week

5

2

XERS Articles
Average Week

Get Xeris Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:XERS) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners